Skip to content

Study · Non-randomized trial · n = 15 · 2018

6 results

Improved glycemic control with once-weekly dulaglutide in addition to insulin therapy in type 2 diabetes mellitus patients on hemodialysis evaluated by continuous glucose monitoring.

Yajima T, Yajima K, Hayashi M, Takahashi H, Yasuda K

Journal of diabetes and its complications21 Dec 2017Cited by 19 (Europe PMC)

PMID29366733 (opens in a new tab)DOI10.1016/j.jdiacomp.2017.12.005 (opens in a new tab)PepBankPUB-29366733
Publisher pagePubMedAsk about this study
Jump to 6 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study6

6 results from studies that gave the peptide. 6 results from people.

  1. 01HumanNon-randomized trialEfficacy outcome

    In insulin-treated T2DM patients on hemodialysis, median insulin dose fell from 12 to 0 U after dulaglutide addition.

    In plain wordsIn T2DM patients on hemodialysis, daily insulin dosage fell compared with before dulaglutide addition.

    Peptide
    Dulaglutide (Trulicity)
    Outcome
    DecreaseDaily insulin dose
    Study

    n = 15

    Comparator
    Before dulaglutide addition
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    Dose not stated

    Measurements

    Median daily insulin dose
    12 U
    before dulaglutide
    Median daily insulin dose, range in parentheses
    12 to 25 U
    before dulaglutide
    Median daily insulin dose
    0 U
    after dulaglutide
    Median daily insulin dose, range in parentheses
    0 to 12 U
    after dulaglutide

    Source sentences

    Summary
    The median total daily insulin dose was reduced significantly from 12 (12-25) to 0 (0-12) U (p < 0.0001) after treatment with dulaglutide.
    3 context sentences
    Summary · context
    Fifteen insulin-treated T2DM patients on hemodialysis were enrolled.
    Summary · context
    Continuous glucose monitoring was performed before (1st hospitalization) and after the fifth dulaglutide administration (2nd hospitalization).
    Summary · context
    The insulin dose was reduced after the first administration of dulaglutide (1st hospitalization day 6).
  2. 02HumanNon-randomized trialEfficacy outcome

    In T2DM patients on hemodialysis, median mean glucose fell from 8.2 to 6.7 mmol/L after dulaglutide addition.

    In plain wordsIn T2DM patients on hemodialysis, average blood sugar fell significantly compared with before dulaglutide addition.

    Peptide
    Dulaglutide (Trulicity)
    Outcome
    DecreaseMean glucose on second hospitalization days 3-4
    Study

    n = 15

    Comparator
    Before dulaglutide addition
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    Dose not stated

    Measurements

    Median mean glucose
    8.2 mmol/L
    first hospitalization days 4-5
    Median mean glucose
    6.7 mmol/L
    second hospitalization days 3-4

    Source sentences

    Summary
    Mean glucose level on 2nd hospitalization days 3-4 significantly decreased and that on days 6-7 tended to decrease compared with that on 1st hospitalization days 4-5 (median, 8.2 to 6.7 mmol/L, P = 0.006 and 8.2 to 6.9 mmol/L, P = 0.053, respectively).
    3 context sentences
    Summary · context
    Fifteen insulin-treated T2DM patients on hemodialysis were enrolled.
    Summary · context
    Continuous glucose monitoring was performed before (1st hospitalization) and after the fifth dulaglutide administration (2nd hospitalization).
    Summary · context
    The insulin dose was reduced after the first administration of dulaglutide (1st hospitalization day 6).
  3. 03HumanNon-randomized trialEfficacy outcome

    In T2DM patients on hemodialysis, median mean glucose tended to decrease from 8.2 to 6.9 mmol/L after dulaglutide addition (P = 0.053).

    In plain wordsIn T2DM patients on hemodialysis, average blood sugar tended to decrease after dulaglutide addition (P = 0.053).

    Peptide
    Dulaglutide (Trulicity)
    Outcome
    DecreaseMean glucose on second hospitalization days 6-7
    Study

    n = 15

    Comparator
    Before dulaglutide addition
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    Dose not stated

    Measurements

    Median mean glucose
    8.2 mmol/L
    first hospitalization days 4-5
    Median mean glucose
    6.9 mmol/L
    second hospitalization days 6-7

    Source sentences

    Summary
    Mean glucose level on 2nd hospitalization days 3-4 significantly decreased and that on days 6-7 tended to decrease compared with that on 1st hospitalization days 4-5 (median, 8.2 to 6.7 mmol/L, P = 0.006 and 8.2 to 6.9 mmol/L, P = 0.053, respectively).
    3 context sentences
    Summary · context
    Fifteen insulin-treated T2DM patients on hemodialysis were enrolled.
    Summary · context
    Continuous glucose monitoring was performed before (1st hospitalization) and after the fifth dulaglutide administration (2nd hospitalization).
    Summary · context
    The insulin dose was reduced after the first administration of dulaglutide (1st hospitalization day 6).
  4. 04HumanNon-randomized trialEfficacy outcome

    In T2DM patients on hemodialysis, glucose coefficient of variation fell from 28.1 to 19.8 after dulaglutide addition.

    In plain wordsIn T2DM patients on hemodialysis, blood sugar variation fell compared with before dulaglutide addition.

    Peptide
    Dulaglutide (Trulicity)
    Outcome
    DecreaseGlucose coefficient of variation on second hospitalization days 3-4
    Study

    n = 15

    Comparator
    Before dulaglutide addition
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    Dose not stated

    Measurements

    Glucose CV
    28.1%
    before dulaglutide
    Glucose CV
    19.8%
    second hospitalization days 3-4

    Source sentences

    Summary
    %CV of glucose levels decreased significantly after dulaglutide administration (28.1 to 19.8, P = 0.003 and 28.1 to 21.0, P = 0.019).
    3 context sentences
    Summary · context
    Fifteen insulin-treated T2DM patients on hemodialysis were enrolled.
    Summary · context
    Continuous glucose monitoring was performed before (1st hospitalization) and after the fifth dulaglutide administration (2nd hospitalization).
    Summary · context
    The insulin dose was reduced after the first administration of dulaglutide (1st hospitalization day 6).
  5. 05HumanNon-randomized trialEfficacy outcome

    In T2DM patients on hemodialysis, glucose coefficient of variation fell from 28.1 to 21.0 after dulaglutide addition.

    In plain wordsIn T2DM patients on hemodialysis, blood sugar variation fell compared with before dulaglutide addition.

    Peptide
    Dulaglutide (Trulicity)
    Outcome
    DecreaseGlucose coefficient of variation on second hospitalization days 6-7
    Study

    n = 15

    Comparator
    Before dulaglutide addition
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    Dose not stated

    Measurements

    Glucose CV
    28.1%
    before dulaglutide
    Glucose CV
    21%
    second hospitalization days 6-7

    Source sentences

    Summary
    %CV of glucose levels decreased significantly after dulaglutide administration (28.1 to 19.8, P = 0.003 and 28.1 to 21.0, P = 0.019).
    3 context sentences
    Summary · context
    Fifteen insulin-treated T2DM patients on hemodialysis were enrolled.
    Summary · context
    Continuous glucose monitoring was performed before (1st hospitalization) and after the fifth dulaglutide administration (2nd hospitalization).
    Summary · context
    The insulin dose was reduced after the first administration of dulaglutide (1st hospitalization day 6).
  6. 06HumanNon-randomized trialSafety outcome

    In T2DM patients on hemodialysis, hypoglycemia incidence remained unchanged after dulaglutide addition.

    In plain wordsIn T2DM patients on hemodialysis, low blood sugar incidence remained unchanged compared with before dulaglutide addition.

    Peptide
    Dulaglutide (Trulicity)
    Outcome
    No significant changeHypoglycemia incidence
    Study

    n = 15

    Comparator
    Before dulaglutide addition
    Outcome group
    Adverse events · Metabolic and weight
    Studied dose
    Dose not stated

    Source sentences

    Summary
    However, the incidence of hypoglycemia remained unchanged.
    3 context sentences
    Summary · context
    Fifteen insulin-treated T2DM patients on hemodialysis were enrolled.
    Summary · context
    Continuous glucose monitoring was performed before (1st hospitalization) and after the fifth dulaglutide administration (2nd hospitalization).
    Summary · context
    The insulin dose was reduced after the first administration of dulaglutide (1st hospitalization day 6).

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    22 Oct 2026, 02:26 UTC

    Study results updated

  2. Version 1

    21 Oct 2026, 18:59 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

PepBank is a research reference. Talk to a doctor before you use any peptide.